A 22-year French experience with solid tumors in children with Down syndrome

Pediatric Hematology and Oncology

Volumn 20, Issue 7, 2003, Pages 517-529

  Satgé, Daniel ^a   Sasco, Annie J ^b   Chompret, Agnès ^c   Orbach, Daniel ^d   Méchinaud, Françoise ^e   Lacour, Brigitte ^f   Roullet, Bernard ^g   Martelli, Hélène ^h   Bergeron, Christophe ⁱ   Bertrand, Yves ^j   Lacombe, Didier ^k   Perel, Yves ^k   Monteil, Pascal ^k   Nelken, Brigitte ^l   Bertozzi, Anne Isabelle ^m   Munzer, Martine ⁿ   Kanold, Justine ^o   Bernard, Fréderic ^p   Vekemans, Michel J ^q   Sommelet, Danièle ^r  

^a CENTRE HOSPITALIER   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT CURIE   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL D ENFANTS   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j HÔPITAL DEBROUSSE   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁿ AMERICAN HOSPITAL OF PARIS   (France)

^o UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^p MONTPELLIER UNIVERSITY HOSPITAL   (France)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

^r UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Child, Down syndrome; Epidemiology; Neoplasms; Solid tumors

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; FRANCE; GERM CELL TUMOR; HUMAN; INFANT; INTRACRANIAL TUMOR; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; PHARMACOGENETICS; SOLID TUMOR;

EID: 12444332624     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390232727     Document Type: Article

References (61)

1. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis, 1. Am J Epidemiol. 2000;151:33-40.
2. Schneid H, Vazquez MP, Vacher C, Gourmelen M, Cabrol S, Le Bouc Y. The Beckwith-Wiedemann syndrome phenotype and the risk of cancer. Med Pediatr Oncol. 1997;28:411-415.
3. Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am J Med Genet. 1998;78:207-216.
4. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
5. Scholl T, Stein Z, Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol. 1982;24:817-829.
6. Boker LK, Blumstein T, Sadetzki S, et al. Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int J Cancer. 2001;93:741-744.
7. Dördelmann M, Schrappe M, Reiter A, et al, for the BFM group. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Leukemia. 1998;12:645-651.
8. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
9. Satgé D, Monteil P, Sasco AJ, et al. Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing grade 2 astrocytoma. Cancer. 2001;91:1458-1466.
10. Satgé D, Gembara P, Sasco AJ, et al. An infant with Down syndrome and retinoblastoma: a possible non-fortuitous association. Ophthalmic Genet. 2001;22:117-123.
11. Berbis P, Beylot C, Noe C, Doutre MS, Broustet A, Privat Y. Xeroderma pigmentosum and refractory anaemia in two first cousins. Br J Dermatol. 1989;121:767-771.
12. Turner JH. The mongoloid phenotype: its incidence, etiology and association with leukemia and other neoplastic disease. Thesis, University of Pittsburg. Ann Arbor, MI: University Microfilms, Inc n° 63-7539;1962.
13. Holland WW, Doll R, Carter CO. The mortality from leukaemia and other cancers among patients with Down's syndrome (mongols) and among their parents. Br J Cancer. 1962;16:177-186.
14. Barber R, Spiers P. Oxford survey of childhood cancers; progress report II. Monthly Bull Minist Health (London). 1964;23:46-52.
15. Jackson EW, Turner JH, Klauber MR, Norris FD. Down's syndrome: variation of leukemia occurrence in institutionalized populations. J Chron Dis. 1968;21:247-253.
16. Miller RW. Childhood cancer and congenital defects, a study of U.S. death certificates during the period 1960-1966. Pediatr Res. 1969;3:389-397.
17. Windham GC, Bjerkedal T, Langmark F. A population-based study of cancer incidence in twins and in children with congenital malformations or low birth weight, Norway 1967-1980. Am J Epidemiol 1985;121:49-56.
18. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 1991;63:993-999.
19. Nishi M, Miyake H, Takeda T, Hatae Y. Congenital malformations and childhood cancer. Med Pediatr Oncol. 2000;34:250-254.
20. Sommelet D, Lacour B. Childhood Cancer Registry of Lorraine, 1983-1992. In: Parkin DM, Kramárová E, Stiller CA, et al, eds. International Incidence of Childhood Cancer. IARC Scientific Publication No 144. Lyon: International Agency for Research on Cancer, 1998:273-275.
21. Little J. Group X: germ-cell, trophoblastic and other gonadal neoplasms. In: Little J, ed. Epidemiology of Childhood Cancer. IARC Scientific Publication No 149. Lyon: International Agency for Research on Cancer, 1999:62-63.
22. Satgé D, Sasco AJ, Curé H, Leduc B, Sommelet D, Vekemans M. An excess of testicular germ cell tumors in Down's syndrome: three cases report and review of the literature. Cancer. 1997;80:929-935.
23. Liu S, Semenciw R, Waters C, Wen SW, Mery LS, Mao Y. Clues to the aetiological heterogeneity of testicular seminomas and non-seminomas: time trends and age-period-cohort effects. Int J Epidemiol. 2000;29:826-831.
24. Flamant F, Caillaud JM, Legal E, Nihoul Fekete C. Tumeurs germinales malignes et des organes génitaux. In: Lemerle J, ed. Cancers de l'Enfant. Paris: Flammarion; 1989:457-480.
25. Satgé D, Le Tourneau A, Verger J-P, et al. A case report of Down syndrome and centroblastic lymphoma. Pathol Res Pract. 1996;192:1266-1269.
26. Sandoval C, Hudson MM, Ozkaynak MF, Tugal O, Jayabose S. Down syndrome and Hodgkin disease in childhood. Med Pediatr Oncol. 2000;34:304-305.
27. Little J. Group V: retinoblastoma. In: Little J, ed. Epidemiology of Childhood Cancer. IARC Scientific Publication No 149. Lyon: International Agency for Research on Cancer, 1999:54-55.
28. Bridge JA, Neff JR, Borek DA, Hackbarth DA. Primary skeletal Ewing's sarcoma in Down syndrome. Cancer Genet Cytogenet. 1990;47:61-68.
29. Miller RW. Relation between cancer and congenital defects in man. N Engl J Med. 1966;275:87-93.
30. Olson JM, Hamilton A, Breslow NE. Non-11p constitutional chromosome abnormalities in Wilms' tumor patients. Med Pediatr Oncol. 1995;24:305-309.
31. Satgé D, Sasco AJ, Carlsen NLT, et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res. 1998;58:448-452.
32. Gonzalez-Crussi F, Upton MP, Maurer HS. Hepatoblastoma: attempt at characterization of histologic subtypes. Am J Surg Pathol. 1982;6:599-612.
33. Koyama T, Kanadani T, Tanaka M, Nakahara S, Yamadori I. A case of Down's syndrome associated with progressive extradural neuroblastoma. Pediatr Surg Int. 1999;15:373-375.
34. Satgé D, Rubie H, Sommelet D. A paravertebral neoplasm in a child with Down syndrome. Pediatr Surg Int. 2001;17:588.
35. Bianca S, Bianca M, Ettore G. Sex ratio imbalance and Down's syndrome newborns. J Perinat Med. 2001;29:266-267.
36. Lorenzana AN, Schorin MA. Non-Hodgkin's lymphoma in a neonate with Down's syndrome. Am J Pediatr Hematol Oncol. 1989;11:186-190.
37. Matsaniotis N, Karpouzas J, Economou-Mavrou C. Hypothyroidism and seminoma in association with Down's syndrome. J Pediatr. 1967;70:810-812.
38. Fekete G. Occurrence of leukemia and other malignancies in the relatives of children with Down syndrome. In: Fekete G, ed. Congenital Chromosome Aberrations and Tumour Predisposition. Budapest: Akademiai Kiado; 1990:40-42.
39. Grech V. An overview and update regarding medical problems in Down syndrome. Indian J Pediatr. 2001;68:863-866.
40. Fabia J, Drolette M. Malformations and leukemia in children with Down's syndrome. Pediatrics. 1970;45:60-70.
41. Iselius L, Jacobs P, Morton N. Leukaemia and transient leukaemia in Down syndrome. Hum Genet. 1990;85:477-485.
42. Shen JJ, Williams BJ, Zipursky A, et al. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet. 1995;56:915-925.
43. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2:429-436.
44. Hennequin M, Morin C, Feine JS. Pain expression and stimulus localisation in individuals with Down's syndrome. Lancet. 2000;356:1882-1887.
45. Sekiguchi Y, Fukuoka H, Ishibashi K, Fujinami K, Kitamura H. A testicular tumor developing in an undescended testis in an adult with Down's syndrome. Kyousai Ihou. 1994;44:281.
46. Chik K-W, Li C-K, Shing MM-K, Leung T-F, Yuen PM-P. Intracranial germ cell tumors in children with and without Down syndrome. J Pediatr Hematol Oncol. 1999;21:149-151.
47. Miki M, Ohtake N, Hasumi M, Ohi M, Moriyama S. Seminoma associated with bilateral cryptorchidism in Down's syndrome: a case report. Int J Urol. 1999;6:377-380.
48. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000;14:786-791.
49. Wada H, Kubo M, Wada T, et al. A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen. No Shinkei Geka. 1995;23:65-68.
50. Grem JL, Trump DL. Reversible increase in serum α-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol. 1986;4:41-45.
51. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524.
52. Belkov VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999;93:1643-1650.
53. Rozga B, Peskin AV, Bartosz G. Effect of carminomycin on the viability of fibroblasts from patients with regular trisomy 21. Free Radic Res Commun. 1990;8:79-83.
54. Przybylska M, Koceva-Chyla A, Rozga B, Jozwiak Z. Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity. Cell Biol Int. 2001;25:157-170.
55. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400.
56. Frost BM, Gustafsson G, Larsson R, Nygren P, Lonnerholm G. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia. 2000;14:943-944.
57. Musarella MA, Verma RS. An infant with Turner-Down aneuploidy and massive capillary hemangioma of the orbit: a case report with review. Ann Genet. 2001;44:67-70.
58. Foley JF, Lemon HM: Down's syndrome associated with an intracranial rhabdomyosarcoma and relative hypopituitarism. Nebr State Med J. 1968;53:384-388.
59. Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med. 1999;19:157-167.
60. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature. 2000;405:311-319.
61. Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet. 2001;17:83-88.